Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case information

REGENXBIO Securities Fraud Class Action

Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.

REGENXBIO · RGX-111 gene therapy · Ongoing Litigation

Last updated

Case overview

Defendant company
REGENXBIO
Product or service
RGX-111 gene therapy
Case status
Ongoing Litigation
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead Plaintiff Application
DJS Law Group lead plaintiff inquiry

Participation information

Availability is based on each listed participation option and its deadline.

Lead Plaintiff Application

Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026, inclusive, and suffered a loss.

Contact the Schall Law Firm to discuss rights and potential participation.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Submit form for REGENXBIO class action information

DJS Law Group lead plaintiff inquiry

Shareholders who purchased REGENXBIO shares from February 9, 2022 through January 27, 2026 and suffered a loss were invited to contact DJS Law Group regarding possible lead plaintiff appointment.

Contact DJS Law Group to discuss rights and possible participation in the case.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear
Original press release Original article

This information does not determine whether you qualify for a case.

Sources

Public reporting associated with this case.